On December 1st, 2015, Meda announced the divestment of the manufacturing unit Euromed in Spain. The divestment has now been completed. The total consideration is EUR 82 million in upfront cash for the shares of Euromed. The unit generates sales of around EUR 40 million and an EBITDA margin of around 20% on an annual basis. For further inquiries, please contact: Paula Treutiger, VP Corporate Communications & Sustainability ph: +46 733 -666 599 paula.treutiger@meda.se MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in more than 150 countries worldwide and the company is represented by its own organizations in over 60 countries. The Meda share is listed under Large Cap on Nasdaq Stockholm. Find out more, visit www.meda.se.
Divestment of manufacturing unit Euromed in Spain completed
| Source: Meda AB
Attachments
